Ciancio G, Burke G W, Jorge D, Rosen A, Miller J
Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Miami, FL 33101, USA.
Minerva Urol Nefrol. 2005 Sep;57(3):141-9.
An overview of the first 4 decades of clinical kidney transplantation would characterize progress primarily in the development of new immunosuppressive agents designed to reduce the incidence and severity of acute rejection to improve short-term outcomes, but with less marked effects on long-term patient and graft survival. The new trend of immunosuppressive therapy is to facilitate long-term allograft and patient survival, and to help to maintain a good quality of life after renal transplantation. To achieve these goals, transplant physicians need to determine the immunosuppressive protocols that will best minimize risk factors associated with reduced allograft/patient survival and quality of life. Recent protocols and clinical experience with modern immunosuppression strategies, as well as the efficacy and safety of various combination protocols, will be reviewed.
临床肾移植头40年的概况表明,进展主要体现在新型免疫抑制剂的研发上,这些药物旨在降低急性排斥反应的发生率和严重程度,以改善短期疗效,但对患者和移植物的长期存活影响较小。免疫抑制治疗的新趋势是促进移植物和患者的长期存活,并有助于维持肾移植后的良好生活质量。为实现这些目标,移植医生需要确定能最大程度降低与移植物/患者存活率及生活质量下降相关风险因素的免疫抑制方案。本文将回顾现代免疫抑制策略的最新方案和临床经验,以及各种联合方案的疗效和安全性。